EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (9)
2024
-
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management
Clinical and Translational Oncology
2022
2021
2020
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
European Journal of Cancer Care, Vol. 29, Núm. 4
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2015
-
SEOM clinical guidelines in early-stage breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945
2014
-
Trastuzumab in small tumours and in elderly women
Cancer Treatment Reviews, Vol. 40, Núm. 1, pp. 41-47
2010
-
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447